References
- BockJThe jubilee of the first successful optic keratoplasty by Eduard ZimWien Klin Wochenschr195870381383 German13570067
- FaridMPirouzianASteinertRFFemtosecond laser keratoplastyInt Ophthalmol Clin201353556423221885
- MaumeneeAEClinical aspects of the corneal homograft reactionInvest Ophthalmol1962124425214471522
- ParksJJLeibowitzHMMaumeneeAEImmediate hypersensitivity reactions in the cornea of the guinea pigJ Immunol19628932332514483968
- GermuthFGMaumeneeAESenterfitLBPollackADImmunohistologic studies on antigen-antibody reactions in the avascular cornea: I. Reactions in rabbits actively sensitized to foreign proteinJ Exp Med196211591992819867210
- ReinhardTBöckingAPomjanskiNSundmacherRImmune cells in the anterior chamber of patients with immune reactions after penetrating keratoplastyCornea200221566111805509
- ErdurmusMCohenEJYildizEHSteroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophyCornea20092875976419574912
- HamrahPDanaMRCorneal antigen-presenting cellsChem Immunol Allergy200792587017264483
- HamrahPHaskovaZTaylorAWZhangQKsanderBRDanaMRLocal treatment with alpha-melanocyte stimulating hormone reduces corneal allorejectionTransplantation20098818018719623012
- MaDHChenHCLaiJYMatrix revolution: molecular mechanism for inflammatory corneal neovascularization and restoration of corneal avascularity by epithelial stem cell transplantationOcul Surf2009712814419635246
- VassilevaPIHergeldzhievaTGAvastin use in high risk corneal transplantationGraefes Arch Clin Exp Ophthalmol20092471701170619680676
- FlynnTHOhbayashiMIkedaYOnoSJLarkinDFEffect of allergic conjunctival inflammation on the allogeneic response to donor corneaInvest Ophthalmol Vis Sci20074894044404917724186
- NguyenPBarteFShinadaSYiuSCManagement of corneal graft rejection – a case series report and review of the literatureJ Clin Exp Ophthalmol20101100010321720570
- HillJCIveyACorticosteroids in corneal graft rejection: double versus single pulse therapyCornea1994133833887995059
- WackerKGründemannCKernYInhibition of corneal inflammation following keratoplasty by birch leaf extractExp Eye Res201297243022360995
- SundmacherRReinhardTHeeringPSix years’ experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective studyGer J Ophthalmol199214324361490144
- StanojlovicSSchlickeiserSAppeltCInfluence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survivalGraefes Arch Clin Exp Ophthalmol20102481447145620574747
- DanaMRYamadaJStreileinJWTopical interleukin 1 receptor antagonist promotes corneal transplant survivalTransplantation199763150115079175817
- GoslingsWRYamadaJDanaMRCorneal transplantation in antibody-deficient hostsInvest Ophthalmol Vis Sci1999402502539888452
- YamadaJDanaMRZhuSNAlardPStreileinJWInterleukin 1 receptor antagonist suppresses allosensitization in corneal transplantationArch Ophthalmol1998116135113579790635
- DanaMRDaiRZhuSYamadaJStreileinJWInterleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilegeInvest Ophthalmol Vis Sci19983970779430547
- RandlemanBJStultingRDPrevention and treatment of corneal graft rejection: current practice patternsCornea20062528629016633028
- RinneJRStultingRDCurrent practices in the prevention and treatment of corneal graft rejectionCornea1992113263281424653
- WangTJWangIJHoJDChouHCLinSYHuangMCComparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority studyClin Ther201032445220171410
- RazeghinejadMRKatzLJSteroid-induced iatrogenic glaucomaOphthalmic Res2012472668021757964
- RachwalSDruzgalaPLiuZZVlasakJBrewsterMEPopEChemistry of loteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compoundsSteroids1998631932019589553
- DruzgalaPHochhausGBodorNSoft drugs – 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonateJ Steroid Biochem Mol Biol1991381491542004037
- AlbertMWuWMWinwoodDBodorNLipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroidJ Biopharm Sci19912115125
- HowesJNovackGDFailure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administrationJ Ocul Pharmacol Ther1998141531589572541
- BodorNBauchwaldPSoft drug design: general principles and recent applicationsMed Res Rev2000205810110608921
- LaneSSHollandEJLoteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgeryJ Cataract Refract Surg20133916817323232255
- StewartRHorwitzBHowesJNovackGDHartKDouble-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1J Cataract Refract Surg199824148014899818338
- ComstockTLUsnerDWEffect of loteprednol etabonate ophthalmic suspension 0.5% on post-operative pain and discomfort. E-abstract. 2010American Society of Cataract and Refractive Surgery SymposiumBoston Convention and Exhibition Center, Boston, MA, USAApril 9–14, 2010
- FongRLeitritzMSiou-MermetRErbTLoteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trialClin Ophthalmol201261113112422888209
- StewartRSControlled evaluation of fluorometholone acetate and loteprednol etabonate in the treatment of postoperative inflammation following cataract surgeryInvest Ophthalmol Vis Sci200445Suppl 1U159
- OnerVTürkcüFMTaşMAlakuşMFIşcanYTopical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safetyJpn J Ophthalmol20125631231822622345
- HolzerMPSolomonKDSandovalHPVromanDTComparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked studyJ Cataract Refract Surg200228939911777716
- RajpalRKSiou-MermetRErbTComstockTResolution of anterior chamber cells and flare with loteprednol etabonate 0.5% gel: new treatment for post-cataract inflammation and pain. E-abstract 1536057. 2013American Society of Cataract and Refractive Surgery SymposiumMoscone Center/SF Marriott Marquis, San Francisco, CA, USAApril 19–23, 2013
- BarkerNHHendersonTRRossCACosterDJWilliamsKACurrent Australian practice in the prevention and management of corneal allograft rejectionClin Experiment Ophthalmol20002835736011097282
- HollandEJDjalilianARSandersonJPAttenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantationCornea2009281139114319770719
- RajpalRKRoelLSiou-MermetRErbTEfficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgeryJ Cataract Refract Surg20133915816723218817
- ComstockTLPaternoMRSinghAErbTDavisESafety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryClin Ophthalmol2011517718621383946
- PoleyBJLindstromRLSamuelsonTWLong-term effects of phacoemulsification with intraocular lens implantation in normotensive and ocular hypertensive eyesJ Cataract Refract Surg20083473574218471626
- HowesJFLoteprednol etabonate: a review of ophthalmic clinical studiesPharmazie20005517818310756536
- ForteLEconomic evaluation of loteprednol etabonate versus prednisolone in treatment of ocular inflammation. Poster abstract #738320. 2010American Society of Cataract and Refractive Surgery SymposiumBoston Convention and Exhibition Center, Boston, MA, USAApril 9–14, 2010
- DruzgalaPWuWMBodorNOcular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyesCurr Eye Res1991109339371959381
- AmonMBusinMLoteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory useInt Ophthalmol20123250751722707339
- HumayunMGottliebCC MDRafusePEIntraocular ophthalmic ointment following clear corneal phacoemulsification: clinical implicationsJ Cataract Refract Surg2006322135213817137997
- AralikattiAKNeedhamADLeeMWPrasadSEntry of antibiotic ointment into the anterior chamber after uneventful phacoemulsificationJ Cataract Refract Surg20032959559712663030
- RiedlMMacaSAmonMNennadalTKrugerABarisaniTIntraocular ointment after small-incision cataract surgery causing chronic uveitis and secondary glaucomaJ Cataract Refract Surg2003291022102512781294
- ChenKHLinSYLiMJChengWTRetained antibiotic ophthalmic ointment on an intraocular lens 34 months after sutureless cataract surgeryAm J Ophthalmol200513974374515808189
- WongJGBankASurgical removal of intraocular antibiotic ointment after routine cataract phacoemulsificationJ Cataract Refract Surg20063289089216765812
- ChewJJLWernerLMackmanGMamalisNLate opacification of a silicone intraocular lens caused by ophthalmic ointmentJ Cataract Refract Surg20063234134616565014
- WernerLSherJHTaylorJRToxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgeryJ Cataract Refract Surg20063222723516564997
- The Loteprednol Etabonate Postoperative Inflammation Study Group 2A double-masked, placebo controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammationOphthalmology1998105178017869754192